NewLink Genetics Corporation (NASDAQ:NLNK) shares fell 1.3% on Tuesday . The stock traded as low as $8.11 and last traded at $8.90. 657,600 shares traded hands during trading, a decline of 50% from the average session volume of 1,305,013 shares. The stock had previously closed at $9.02.
Several research firms have recently weighed in on NLNK. Zacks Investment Research lowered shares of NewLink Genetics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, November 8th. ValuEngine lowered shares of NewLink Genetics Corporation from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 26th. Cantor Fitzgerald restated a “buy” rating and set a $26.00 price objective on shares of NewLink Genetics Corporation in a research note on Thursday, November 2nd. Jefferies Group LLC lowered their price objective on shares of NewLink Genetics Corporation from $26.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, November 3rd. Finally, Stifel Nicolaus lifted their target price on shares of NewLink Genetics Corporation from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. NewLink Genetics Corporation has an average rating of “Buy” and an average target price of $23.43.
In other NewLink Genetics Corporation news, major shareholder Stine Seed Farm, Inc. acquired 780,487 shares of the business’s stock in a transaction on Friday, October 6th. The stock was purchased at an average price of $10.25 per share, with a total value of $7,999,991.75. Following the acquisition, the insider now directly owns 7,857,732 shares of the company’s stock, valued at approximately $80,541,753. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 13.70% of the company’s stock.
About NewLink Genetics Corporation
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.